Ganz, Joranson receive ACS Distinguished Service Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.

ATLANTA—The American Cancer Society has given its Distinguished Service Award to Patricia Ganz, MD, director of cancer prevention and control research at UCLA's Jonsson Cancer Center, and to David E. Joranson, MSSW, Distinguished Scientist and recently retired director of the Pain and Policy Studies Group at the University of Wisconsin Carbone Comprehensive Cancer Center.

Dr. Ganz, a professor in the UCLA Schools of Medicine and Public Health and a founding member of the National Coalition for Cancer Survivorship, was recognized for her major contributions and commitment in the field of cancer research. For 2 decades, Dr. Ganz has conducted ground-breaking research that has changed the face of cancer survivorship. Last year, she was selected to head up the UCLA-Livestrong Survivorship Center of Excellence, which addresses the needs of the ever-increasing number of cancer survivors in the United States.

Mr. Joranson was honored for his contributions to the study and modernization of narcotics control policies to remove barriers to pain patients' access to opioid analgesics, ACS said. As director of the World Health Organization Collaborating Center for Policy and Communications in Cancer Care, he has led efforts to achieve more balanced national drug control policies and improve patient access to pain drugs in developing countries.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content